The article says unit-to-milligram conversions differ between formats, which is exactly why it calls provider clarification essential rather than something to work out with arithmetic
When it comes to diet, the principles discussed above dont vary by GLP-1 type
According to the Wegovy Summary of Product Characteristics (SmPC), injection site reactions are reported as 'common' (affecting between 1 in 10 and 1 in 100 people), while hypersensitivity reactions including urticaria are classified as 'uncommon' (affecting between 1 in 100 and 1 in 1,000 people)
Make sure to drink water and rest
Rybelsus and Intermittent Fasting: Safety, Timing and NHS Guidance Rybelsus (semaglutide) is an oral GLP-1 receptor agonist licensed in the UK for type 2 diabetes management, whilst intermittent fasting has gained attention as a dietary approach to improve metabolic health
Lixisenatide from Zealand Pharma was approved in June 2013, targeting type 2 diabetes